Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., according to CEO Thomas Schinecker, who declined to reveal what these assets are.

Roche said on Tuesday it would invest $50 billion in the United States over the next five years, creating more than 12,000 new jobs, in the latest massive investment by companies reacting to President Donald Trump's tariff policy.

Roche is pledging to invest $50 billion in manufacturing and research infrastructure in the U.S. over the next five years, making the pharmaceutical giant the latest company to unveil a capital expenditure push as drugmakers prepare for expected tariffs from the Trump administration.